世界卫生组织去年推荐各国扩大使用长效注射HIV预防药物lenacapavir[1]。这款药物是PrEP的注射版本，每年仅需两次注射，对持续使用者预防性传播HIV的有效性达99%[1]。专家在里约热内卢艾滋病2026大会上指出，这类新型HIV预防创新可以大幅降低全球新增感染病例[1]。
然而，美国外援削减将阻碍最需要这类药物的贫困人群获得使用[1]。随着全球HIV预防投资大幅下降，原本有望惠及广泛人口的预防方案面临可及性危机[1]。
Experts gathered at the 2026 AIDS Conference in Rio de Janeiro have highlighted the potential of lenacapavir, an injectable form of HIV prevention medication, to significantly reduce global infection rates, yet warned that U.S. foreign aid reductions may prevent access for those most in need.[1]
The World Health Organization recommended that countries prioritize expanding use of lenacapavir approximately one year ago.[1] The drug requires only two injections annually and demonstrates 99 percent effectiveness in preventing sexual transmission of HIV among consistent users.[1] According to experts, this innovative approach to HIV prevention could substantially lower new infection cases worldwide.[1] However, USAID's cuts to foreign assistance threaten to block the poorest populations from obtaining this new preventive treatment.[1] Global HIV prevention investment has already declined, further limiting options for vulnerable communities.[1]